In clinical trials of the Alzheimer’s treatment Aduhelm (aducanumab), participants who experienced a greater reduction in brain levels of amyloid plaques — the abnormal protein clumps targeted by the treatment — tended to also experience a greater treatment benefit, in terms of cognition and functional ability, according to new analyses. The findings broadly support Aduhelm’s proposed mechanism of action, whereby removing amyloid plaques prevents damage in the brain and, consequently, cognitive problems. Aduhelm, which was…
You must be logged in to read/download the full post.
The post #AAIC21 – New Analyses Support Aduhelm’s Effects on Cognition appeared first on BioNewsFeeds.